CEFTRIAXONE Drug Patent Profile

Which patents cover Ceftriaxone, and when can generic versions of Ceftriaxone launch?

Ceftriaxone is a drug marketed by Acs Dobfar, Agila Speclts, Apotex, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu Antibiotics, Samson Medcl, Sandoz, Sandoz Inc, Teva, Astral, Cephazone Pharma, Deva Holding As, Epic Pharma Llc, Hikma Farmaceutica, Teva Pharms Usa, Wockhardt Bio Ag, B Braun, Baxter Hlthcare, Anda Repository, and Hikma. and is included in thirty-seven NDAs.

The generic ingredient in CEFTRIAXONE is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ceftriaxone

A generic version of CEFTRIAXONE was approved as ceftriaxone sodium by ANDA REPOSITORY on January 20^th, 2017.

Summary for CEFTRIAXONE

US Patents:	0
Applicants:	25
NDAs:	37
Finished Product Suppliers / Packagers:	15
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	196
Drug Prices:	Drug price information for CEFTRIAXONE
DailyMed Link:	CEFTRIAXONE at DailyMed

See drug prices for CEFTRIAXONE

Recent Clinical Trials for CEFTRIAXONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE3
University of Virginia	PHASE3
University of Belgrade	NA

See all CEFTRIAXONE clinical trials

Pharmacology for CEFTRIAXONE

Drug Class

Cephalosporin Antibacterial

US Patents and Regulatory Information for CEFTRIAXONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065169-002	May 9, 2005	AP	RX	No	Yes
Deva Holding As	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	210197-001	Jan 12, 2024		DISCN	No	No
Bedford	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065465-004	Aug 18, 2008		DISCN	No	No
Anda Repository	CEFTRIAXONE SODIUM	ceftriaxone sodium	INJECTABLE;INJECTION	091117-001	Jan 20, 2017	AP	RX	No	No
Fresenius Kabi Usa	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065245-003	Feb 15, 2006		DISCN	No	No

Market Dynamics and Financial Trajectory for Ceftriaxone

Last updated: February 24, 2026

What is the current market size for Ceftriaxone?

Ceftriaxone, a broad-spectrum third-generation cephalosporin antibiotic, generated approximately $1.4 billion globally in 2022. The compound is primarily administered via injection and used to treat bacterial infections such as pneumonia, meningitis, and urinary tract infections.

How is demand for Ceftriaxone evolving?

Demand is driven by rising bacterial resistance, increasing infection rates, and expanding indications. The Asia-Pacific region accounts for nearly 40% of global sales, with China and India leading growth due to healthcare infrastructure expansions and higher infection prevalence.

What are the key factors impacting market growth?

Patent and Regulatory Status

Ceftriaxone has lost patent exclusivity in many markets, including the U.S. and Europe. Several generics are available, intensifying price competition and exerting downward pressure on revenue.

Manufacturing and Supply Chain

Manufacturing complexity due to the need for sterile processing and quality controls influences supply. Disruptions can cause price fluctuations and influence market access.

Pricing and Reimbursement Policies

Pricing is subject to regional reimbursement schemes. Countries with centralized healthcare systems implement price controls, limiting revenue growth.

Competition

Generic manufacturers dominate the market. Emerging alternatives, such as newer antibiotics with broader spectra or lower administration costs, threaten market share.

What is the projected financial trajectory?

Revenue Trends

Analysts project a compound annual growth rate (CAGR) of approximately 2.5% over the next five years, reaching roughly $1.55 billion by 2027. Slower growth results from patent expiry and increased generic competition.

Price Dynamics

Prices for branded Ceftriaxone vary from $20 to $50 per vial, depending on the region. Generics are priced 10–20% lower, further pressuring revenue.

Market Share Distribution

Generics command about 85% of total sales, with branded products holding the remainder. Large pharmaceutical firms focusing on branded formulations for niche indications maintain smaller market shares.

Investment and R&D Trends

Despite mature status, investment persists in formulations that enable easier administration or address resistant strains. Biotech firms explore novel delivery mechanisms, potentially impacting future pricing and market dynamics.

How do regional regulations affect the market?

Regulatory approvals for new formulations or indications can lead to short-term sales boosts. Conversely, restrictive policies, especially in Europe and North America, limit incremental revenue.

What are emerging challenges and opportunities?

Challenges

• Increasing antimicrobial resistance diminishes treatment efficacy.
• Stringent quality and safety standards complicate manufacturing.
• Price control policies limit profit margins.

Opportunities

• Developing combination therapies to extend patent life.
• Expanding use in emerging markets.
• Investing in formulations with simplified administration.

Summary Table: Key Market Data

Parameter	2022 Data	projection (2027)
Global Market Size	$1.4 billion	$1.55 billion
CAGR	—	2.5%
Regional Market Share	North America: 35%, Asia-Pacific: 40%, Europe: 20%, Others: 5%	—
Price Per Vial	$20–$50	Stable, but downward pressure persists

Key Takeaways

Ceftriaxone remains a significant antibiotic, with steady but slowing growth influenced by patent expiration, market competition, and regional pricing pressures. Future revenues depend on market expansion in emerging economies, development of novel formulations, and addressing antimicrobial resistance challenges.

FAQs

What are the main drivers of Ceftriaxone market growth?

Increased bacterial infections, expanding indications, and emerging markets. Resistance to other antibiotics also favors Ceftriaxone use.

How does patent expiry influence Ceftriaxone sales?

Loss of patent protection enables generic manufacturers to enter markets, reducing prices and shrinking branded revenue share.

Which regions represent the largest opportunities?

Asia-Pacific leads growth potential, driven by population size, infrastructure development, and rising infection rates.

What are the key regulatory hurdles for Ceftriaxone?

Regulatory agencies require extensive safety and efficacy data, especially for new formulations and indications, which can delay market entry.

How might antimicrobial resistance affect the outlook?

Rising resistance diminishes Ceftriaxone's effectiveness, potentially reducing its clinical use and prompting shifts toward alternative treatments.

References

1. MarketWatch. (2023). Ceftriaxone market size and forecast, 2022-2027. Retrieved from https://www.marketwatch.com
2. GlobalData. (2022). Antibiotics market report. Retrieved from https://www.globaldata.com
3. IQVIA. (2022). Healthcare trends and antibiotic sales data. Retrieved from https://www.iqvia.com
4. WHO. (2021). Antimicrobial resistance factsheet. https://www.who.int